Filius Bart 4

What Happened Filius Bart, a director of ProQR Therapeutics N.V. (PRQR), acquired 150,000 shares in an open-market purchase on July 17, 2026. The shares were bought at $1.72 per share for a total transaction value of $257,925. This was a buy (purchase) rather than a sale.

Key Details

• Transaction date: 2026-07-17; Filing date (Form 4): 2026-07-21 (filed within the two-business-day window).
• Transaction type/code: Open-market purchase (P).
• Price and amount: 150,000 shares at $1.72 per share; total $257,925.
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes/plan: No 10b5-1 plan, tax withholding, or other special footnotes disclosed in the supplied details.

Context Purchases by directors are often viewed by investors as a positive signal, but the filing does not disclose the insider’s motivation. This transaction appears routine and was reported timely under SEC Form 4 rules.